Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference
- PMID: 29232472
- PMCID: PMC5834101
- DOI: 10.1093/annonc/mdx449
Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference
Abstract
The Gynecologic Cancer InterGroup (GCIG) Fifth Ovarian Cancer Consensus Conference (OCCC) was held in Tokyo, Japan from 7 to 9 November 2015. It provided international consensus on 15 important questions in 4 topic areas, which were generated in accordance with the mission statement to establish 'International Consensus for Designing Better Clinical Trials'. The methodology for obtaining consensus was previously established and followed during the Fifth OCCC. All 29 clinical trial groups of GCIG participated in program development and deliberations. Draft consensus statements were discussed in topic groups as well as in a plenary forum. The final statements were then presented to all 29 member groups for voting and documentation of the level of consensus. Full consensus was obtained for 11 of the 15 statements with 28/29 groups agreeing to 3 statements, and 27/29 groups agreeing to 1 statement. The high acceptance rate of the statements among trial groups reflects the fact that we share common questions, and recognise important unmet needs that will guide future research in ovarian cancer.
Keywords: clinical trial; consensus statement; ovarian cancer.
© The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Similar articles
-
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.Lancet Oncol. 2022 Aug;23(8):e374-e384. doi: 10.1016/S1470-2045(22)00139-5. Lancet Oncol. 2022. PMID: 35901833 Free PMC article. Review.
-
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours.Ann Oncol. 2017 Apr 1;28(4):718-726. doi: 10.1093/annonc/mdw662. Ann Oncol. 2017. PMID: 27993794 Free PMC article.
-
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).Ann Oncol. 2005;16 Suppl 8:viii7-viii12. doi: 10.1093/annonc/mdi961. Ann Oncol. 2005. PMID: 16239238 No abstract available.
-
Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors.Ann Oncol. 2017 Apr 1;28(4):702-710. doi: 10.1093/annonc/mdx010. Ann Oncol. 2017. PMID: 28119296
-
Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup.Lancet Oncol. 2024 Sep;25(9):e420-e431. doi: 10.1016/S1470-2045(24)00192-X. Lancet Oncol. 2024. PMID: 39214113
Cited by
-
COM33 suppresses carboplatin-induced epithelial-mesenchymal transition via inhibition of Twist1 in ovarian cancer.Acta Biochim Biophys Sin (Shanghai). 2022 Dec 25;55(1):34-42. doi: 10.3724/abbs.2022195. Acta Biochim Biophys Sin (Shanghai). 2022. PMID: 36647720 Free PMC article.
-
Establishment of an ovarian cancer omentum metastasis-related prognostic model by integrated analysis of scRNA-seq and bulk RNA-seq.J Ovarian Res. 2022 Nov 23;15(1):123. doi: 10.1186/s13048-022-01059-0. J Ovarian Res. 2022. PMID: 36424614 Free PMC article.
-
Characteristics of clinical trials for non-small cell lung cancer therapeutic vaccines registered on ClinicalTrials.gov.Front Immunol. 2022 Oct 19;13:936667. doi: 10.3389/fimmu.2022.936667. eCollection 2022. Front Immunol. 2022. PMID: 36341464 Free PMC article. Clinical Trial.
-
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.Lancet Oncol. 2022 Aug;23(8):e374-e384. doi: 10.1016/S1470-2045(22)00139-5. Lancet Oncol. 2022. PMID: 35901833 Free PMC article. Review.
-
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.Lancet Oncol. 2022 Jul;23(7):919-930. doi: 10.1016/S1470-2045(22)00283-2. Epub 2022 Jun 9. Lancet Oncol. 2022. PMID: 35690073 Free PMC article. Clinical Trial.
References
-
- Neijt JP, Wiltshaw E, Lund B (eds), Advanced epithelial ovarian cancer: where do we stand and where do we go? Ann Oncol 1993; 4(Suppl 4): S1–S88.
-
- Neijt JP, du Bois A, Williams C (eds), Advanced epithelial ovarian cancer—what do we know and what do we need? Ann Oncol 1999; 10(Suppl 1): S1–S92.
-
- du Bois A, Quinn M, Thigpen T. et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005; 16(Suppl 8): viii7–viii12. - PubMed
-
- Stuart GCE, Kitchener H, Bacon M. et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer report from the fourth ovarian cancer consensus conference. Int J Gynecol Cancer 2001; 21: 750–755. - PubMed
-
- McGee J, Bookman M, Harter P. et al. Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors. Ann Oncol 2017; 28: 702–710. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical